Stem cells with decellularized liver scaffolds in liver regeneration and their potential clinical applications

Liver International

Volumn 35, Issue 3, 2015, Pages 687-694

  Zhou, Qian ^a   Li, Lanjuan ^a   Li, Jun ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Endothelialisation; Liver perfusion; Mesenchymal stem cells; Scaffold; Surface modification; Transplantation

Indexed keywords

ANTICOAGULATION; CELL COUNT; END STAGE LIVER DISEASE; EXTRACELLULAR MATRIX; HEPATOCYTE TRANSPLANTATION; HUMAN; LIVER REGENERATION; REVIEW; STEM CELL; TISSUE ENGINEERING; TISSUE SCAFFOLD; ANIMAL; CYTOLOGY; LIVER CELL; LIVER TRANSPLANTATION; MESENCHYMAL STROMA CELL; MOUSE; PERFUSION; PIG; PROCEDURES; RAT; TRANSPLANTATION;

ANIMALS; END STAGE LIVER DISEASE; EXTRACELLULAR MATRIX; HEPATOCYTES; HUMANS; LIVER REGENERATION; LIVER TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; PERFUSION; RATS; SWINE; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 84922692170     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12581     Document Type: Review

References (87)

1. Klein AS, Messersmith EE, Ratner LE, et al. Organ donation and utilization in the United States, 1999-2008. Am J Transplant 2010; 10(4 Pt 2): 973-86.
2. Moreno R, Berenguer M. Post-liver transplantation medical complications. Ann Hepatol 2006; 5: 77-85.
3. Lorenzini S, Gitto S, Grandini E, Andreone P, Bernardi M. Stem cells for end stage liver disease: how far have we got? World J Gastroenterol 2008; 14: 4593-9.
4. Nussler A, Konig S, Ott M, et al. Present status and perspectives of cell-based therapies for liver diseases. J Hepatol 2006; 45: 144-59.
5. Piscaglia AC, Campanale M, Gasbarrini A, Gasbarrini G. Stem cell-based therapies for liver diseases: state of the art and new perspectives. Stem Cells Int 2010; 2010: 259461.
6. Strain AJ, Neuberger JM. A bioartificial liver-state of the art. Science 2002; 295: 1005-9.
7. Du Y, Chia SM, Han R, et al. 3D hepatocyte monolayer on hybrid RGD/galactose substratum. Biomaterials 2006; 27: 5669-80.
8. Faraj KA, van Kuppevelt TH, Daamen WF. Construction of collagen scaffolds that mimic the three-dimensional architecture of specific tissues. Tissue Eng 2007; 13: 2387-94.
9. Glicklis R, Shapiro L, Agbaria R, Merchuk JC, Cohen S Hepatocyte behavior within three-dimensional porous alginate scaffolds. Biotechnol Bioeng 2000; 67: 344-53.
10. Jiang J, Kojima N, Guo L, et al. Efficacy of engineered liver tissue based on poly-L-lactic acid scaffolds and fetal mouse liver cells cultured with oncostatin M, nicotinamide, and dimethyl sulfoxide. Tissue Eng 2004; 10: 1577-86.
11. Lan SF, Safiejko-Mroczka B, Starly B. Long-term cultivation of HepG2 liver cells encapsulated in alginate hydrogels: a study of cell viability, morphology and drug metabolism. Toxicol In Vitro 2010; 24: 1314-23.
12. Li J, Tao R, Wu W, et al. 3D PLGA scaffolds improve differentiation and function of bone marrow mesenchymal stem cell-derived hepatocytes. Stem Cells Dev 2010; 19: 1427-36.
13. Li YS, Harn HJ, Hsieh DK, et al. Cells and materials for liver tissue engineering. Cell Transplant 2013; 22: 685-700.
14. Provin C, Takano K, Sakai Y, Fujii T, Shirakashi R, et al. A method for the design of 3D scaffolds for high-density cell attachment and determination of optimum perfusion culture conditions. J Biomech 2008; 41: 1436-49.
15. Soto-Gutierrez A, Kobayashi N, Rivas-Carrillo JD, et al. Reversal of mouse hepatic failure using an implanted liver-assist device containing ES cell-derived hepatocytes. Nat Biotechnol 2006; 24: 1412-9.
16. Kim SS, Utsunomiya H, Koski JA, et al. Survival and function of hepatocytes on a novel three-dimensional synthetic biodegradable polymer scaffold with an intrinsic network of channels. Ann Surg 1998; 228: 8-13.
17. Wang Y, Cui CB, Yamauchi M, et al. Lineage restriction of human hepatic stem cells to mature fates is made efficient by tissue-specific biomatrix scaffolds. Hepatology 2011; 53: 293-305.
18. Badylak SF, Taylor D, Uygun K. Whole-organ tissue engineering: decellularization and recellularization of three-dimensional matrix scaffolds. Annu Rev Biomed Eng 2011; 13: 27-53.
19. Moon JJ, West JL. Vascularization of engineered tissues: approaches to promote angio-genesis in biomaterials. Curr Top Med Chem 2008; 8: 300-10.
20. Baharvand H, Hashemi SM, Kazemi Ashtiani S, Farrokhi A. Differentiation of human embryonic stem cells into hepatocytes in 2D and 3D culture systems in vitro. Int J Dev Biol 2006; 50: 645-52.
21. Miki T, Ring A, Gerlach J. Hepatic differentiation of human embryonic stem cells is promoted by three-dimensional dynamic perfusion culture conditions. Tissue Eng Part C Methods 2011; 17: 557-68.
22. Mahdavi Shahri N, Baharara J, Takbiri M, Khajeh Ahmadi S. In vitro decellularization of rabbit lung tissue. Cell J 2013; 15: 83-8.
23. Nichols JE, Niles J, Riddle M, et al. Production and assessment of decellularized pig and human lung scaffolds. Tissue Eng Part A 2013; 19: 2045-62.
24. Arenas-Herrera JE, Ko IK, Atala A, Yoo JJ. Decellularization for whole organ bioengineering. Biomed Mater 2013; 8: 014106.
25. Sullivan DC, Mirmalek-Sani SH, Deegan DB, et al. Decellularization methods of porcine kidneys for whole organ engineering using a high-throughput system. Biomaterials 2012; 33: 7756-64.
26. Remlinger NT, Wearden PD, Gilbert TW. Procedure for decellularization of porcine heart by retrograde coronary perfusion. J Vis Exp 2012; 70: e50059.
27. Woods T, Gratzer PF. Effectiveness of three extraction techniques in the development of a decellularized bone-anterior cruciate ligament-bone graft. Biomaterials 2005; 26: 7339-49.
28. Badylak SF. The extracellular matrix as a biologic scaffold material. Biomaterials 2007; 28: 3587-93.
29. Baptista PM, Orlando G, Mirmalek-Sani SH, et al. Whole organ decellularization - a tool for bioscaffold fabrication and organ bioengineering. Conf Proc IEEE Eng Med Biol Soc 2009; 2009: 6526-9.
30. Ott HC, Matthiesen TS, Goh SK, et al. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat Med 2008; 14: 213-21.
31. Prasertsung I, Kanokpanont S, Bunaprasert T, Thanakit V, Damrongsakkul S. Development of acellular dermis from porcine skin using periodic pressurized technique. J Biomed Mater Res B Appl Biomater 2008; 85: 210-9.
32. Gui L, Chan S A, Breuer C K, Niklason LE. Novel utilization of serum in tissue decellularization. Tissue Eng Part C Methods 2010; 16: 173-84.
33. Shupe T, Williams M, Brown A, Willenberg B, Petersen BE. Method for the decellularization of intact rat liver. Organogenesis 2010; 6: 134-6.
34. Kasimir MT, Rieder E, Seebacher G, et al. Comparison of different decellularization procedures of porcine heart valves. Int J Artif Organs 2003; 26: 421-7.
35. Reing JE, Brown BN, Daly KA, et al. The effects of processing methods upon mechanical and biologic properties of porcine dermal extracellular matrix scaffolds. Biomaterials 2010; 31: 8626-33.
36. Bao J, Shi Y, Sun H, et al. Construction of a portal implantable functional tissue-engineered liver using perfusion-decellularized matrix and hepatocytes in rats. Cell Transplant 2011; 20: 753-66.
37. De Kock J, Ceelen L, De Spiegelaere W, et al. Simple and quick method for whole-liver decellularization: a novel in vitro three-dimensional bioengineering tool? Arch Toxicol 2011; 85: 607-12.
38. Zhou P, Lessa N, Estrada DC, et al. Decellularized liver matrix as a carrier for the transplantation of human fetal and primary hepatocytes in mice. Liver Transpl 2011; 17: 418-27.
39. Uygun BE, Soto-Gutierrez A, Yagi H, et al. Organ reengineering through development of a transplantable recellularized liver graft using decellularized liver matrix. Nat Med 2010; 16: 814-20.
40. Cebotari S, Tudorache I, Jaekel T, et al. Detergent decellularization of heart valves for tissue engineering: toxicological effects of residual detergents on human endothelial cells. Artif Organs 2010; 34: 206-10.
41. Soto-Gutierrez A, Zhang L, Medberry C, et al. A whole-organ regenerative medicine approach for liver replacement. Tissue Eng Part C Methods 2011; 17: 677-86.
42. Park KM, Woo HM. Porcine bioengineered scaffolds as new frontiers in regenerative medicine. Transplant Proc 2012; 44: 1146-50.
43. Lin P, Chan WC, Badylak SF, Bhatia SN. Assessing porcine liver-derived biomatrix for hepatic tissue engineering. Tissue Eng 2004; 10: 1046-53.
44. Clayton DF, Darnell JE Jr. Changes in liver-specific compared to common gene transcription during primary culture of mouse hepatocytes. Mol Cell Biol 1983; 3: 1552-61.
45. Quante M, Wang TC. Stem cells in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol 2009; 6: 724-37.
46. Yanagida A, Ito K, Chikada H, Nakauchi H, Kamiya A. An in vitro expansion system for generation of human iPS cell-derived hepatic progenitor-like cells exhibiting a bipotent differentiation potential. PLoS ONE 2013; 8: e67541.
47. Baptista PM, Siddiqui MM, Lozier G, et al. The use of whole organ decellularization for the generation of a vascularized liver organoid. Hepatology 2011; 53: 604-17.
48. Yagi H, Parekkadan B, Suganuma K, et al. Long-term superior performance of a stem cell/hepatocyte device for the treatment of acute liver failure. Tissue Eng Part A 2009; 15: 3377-88.
49. Lees JG, Lim SA, Croll T, et al. Transplantation of 3D scaffolds seeded with human embryonic stem cells: biological features of surrogate tissue and teratoma-forming potential. Regen Med 2007; 2: 289-300.
50. Subba Rao M, Sasikala M, Nageshwar Reddy D. Thinking outside the liver: induced pluripotent stem cells for hepatic applications. World J Gastroenterol 2013; 19: 3385-96.
51. Behbahan IS, Duan Y, Lam A, et al. New approaches in the differentiation of human embryonic stem cells and induced pluripotent stem cells toward hepatocytes. Stem Cell Rev 2011; 7: 748-59.
52. Si-Tayeb K, Noto F K, Nagaoka M, et al. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology 2010; 51: 297-305.
53. Lu TY, Lin B, Kim J, et al. Repopulation of decellularized mouse heart with human induced pluripotent stem cell-derived cardiovascular progenitor cells. Nat Commun 2013; 4: 2307.
54. Woltjen K, Michael IP, Mohseni P, et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009; 458: 766-70.
55. Kaji K, Norrby K, Paca A, et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009; 458: 771-5.
56. In 'T Anker TPS, Noort WA, Scherjon SA, et al., Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica 2003; 88: 845-52.
57. Ge X, Bai C, Yang J, et al. Intratracheal transplantation of bone marrow-derived mesenchymal stem cells reduced airway inflammation and up-regulated CD4(+)CD25(+) regulatory T cells in asthmatic mouse. Cell Biol Int 2013; 37: 675-86.
58. Li J, Zhang L, Xin J, et al. Immediate intraportal transplantation of human bone marrow mesenchymal stem cells prevents death from fulminant hepatic failure in pigs. Hepatology 2012; 56: 1044-52.
59. Ji R, Zhang N, You N, et al. The differentiation of MSCs into functional hepatocyte-like cells in a liver biomatrix scaffold and their transplantation into liver-fibrotic mice. Biomaterials 2012; 33: 8995-9008.
60. Sussman NL, Kelly JH. Artificial liver: a forthcoming attraction. Hepatology 1993; 17: 1163-4.
61. Fitzpatrick E, Mitry RR, Dhawan A. Human hepatocyte transplantation: state of the art. J Intern Med 2009; 266: 339-57.
62. Soto-Gutierrez A, Navarro-Alvarez N, Yagi H, et al. Engineering of an hepatic organoid to develop liver assist devices. Cell Transplant 2010; 19: 815-22.
63. Kim SS, Sundback CA, Kaihara S, et al. Dynamic seeding and in vitro culture of hepatocytes in a flow perfusion system. Tissue Eng 2000; 6: 39-44.
64. Ohashi K, Waugh JM, Dake MD, et al. Liver tissue engineering at extrahepatic sites in mice as a potential new therapy for genetic liver diseases. Hepatology 2005; 41: 132-40.
65. Alvarez CV, Garcia-Lavandeira M, Garcia-Rendueles ME, et al. Defining stem cell types: understanding the therapeutic potential of ESCs, ASCs, and iPS cells. J Mol Endocrinol 2012; 49: R89-111.
66. Kaufmann PM, Sano K, Uyama S, Takeda T, Vacanti JP, et al. Heterotopic hepatocyte transplantation: assessing the impact of hepatotrophic stimulation. Transplant Proc 1994; 26: 2240-1.
67. Lee HB, Blaufox MD. Blood volume in the rat. J Nucl Med 1985; 26: 72-6.
68. Rosenman JE, Kempczinski RF, Pearce WH, Silberstein EB. Kinetics of endothelial cell seeding. J Vasc Surg 1985; 2: 778-84.
69. Martin I, Wendt D, Heberer M. The role of bioreactors in tissue engineering. Trends Biotechnol 2004; 22: 80-6.
70. Guthrie R. Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events. Adv Ther 2011; 28: 473-82.
71. Rojas-Hernandez CM, Garcia DA. The novel oral anticoagulants. Semin Thromb Hemost 2013; 39: 117-26.
72. Lee KB, Yoon KR, Woo SI, Choi IS Surface modification of poly(glycolic acid) (PGA) for biomedical applications. J Pharm Sci 2003; 92: 933-7.
73. Ma Z, Mao Z, Gao C. Surface modification and property analysis of biomedical polymers used for tissue engineering. Colloids Surf B Biointerfaces 2007; 60: 137-57.
74. Zhang J, Senger B, Vautier D, et al. Natural polyelectrolyte films based on layer-by layer deposition of collagen and hyaluronic acid. Biomaterials 2005; 26: 3353-61.
75. Samuel RE, Shukla A, Paik DH, et al. Osteoconductive protamine-based polyelectrolyte multilayer functionalized surfaces. Biomaterials 2011; 32: 7491-502.
76. Shirakigawa N, Ijima H, Takei T. Decellularized liver as a practical scaffold with a vascular network template for liver tissue engineering. J Biosci Bioeng 2012; 114: 546-51.
77. Yi W, Sun Y, Wei X, et al. Proteomic profiling of human bone marrow mesenchymal stem cells under shear stress. Mol Cell Biochem 2010; 341: 9-16.
78. Tassiopoulos AK, Greisler HP. Angiogenic mechanisms of endothelialization of cardiovascular implants: a review of recent investigative strategies. J Biomater Sci Polym Ed 2000; 11: 1275-84.
79. Bowlin GL, Rittgers SE. Electrostatic endothelial cell seeding technique for small-diameter (<6 mm) vascular prostheses: feasibility testing. Cell Transplant 1997; 6: 623-9.
80. Brewster L, Brey EM, Addis M, et al. Improving endothelial healing with novel chimeric mitogens. Am J Surg 2006; 192: 589-93.
81. Shireman PK, Xue L, Maddox E, Burgess WH, Greisler HP. The S130K fibroblast growth factor-1 mutant induces heparin-independent proliferation and is resistant to thrombin degradation in fibrin glue. J Vasc Surg 2000; 31: 382-90.
82. Xue L, Tassiopoulos AK, Woloson SK, et al. Construction and biological characterization of an HB-GAM/FGF-1 chimera for vascular tissue engineering. J Vasc Surg 2001; 33: 554-60.
83. Golomb G, Ezra V. Covalent binding of protamine by glutaraldehyde to bioprosthetic tissue: characterization and anticalcification effect. Biomater Artif Cells Immobilization Biotechnol 1992; 20: 31-41.
84. Kaully T, Kaufman-Francis K, Lesman A, Levenberg S. Vascularization-the conduit to viable engineered tissues. Tissue Eng Part B Rev 2009; 15: 159-69.
85. Zhang J, Zhang XZ, Zhang Y. Role of mesenchymal stem cells in angiogenesis and clinical applications. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010; 18: 1084-7.
86. Wang Z, He Y, Yu X, et al. Rapid vascularization of tissue-engineered vascular grafts in vivo by endothelial cells in co-culture with smooth muscle cells. J Mater Sci Mater Med 2012; 23: 1109-17.
87. Petersen TH, Calle EA, Zhao L, et al. Tissue-engineered lungs for in vivo implantation. Science 2010; 329: 538-41.